

# Diagnosis and Treatment of Interstitial Cystitis/Bladder Amendment

Journal of Urology

193, 1545-1553

DOI: [10.1016/j.juro.2015.01.086](https://doi.org/10.1016/j.juro.2015.01.086)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Editorial Comment from Dr Manning to Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response. International Journal of Urology, 2015, 22, 842-843.	0.5	0
2	Assessment of colon and bladder crosstalk in an experimental colitis model using contrast-enhanced magnetic resonance imaging. Neurogastroenterology and Motility, 2015, 27, 1571-1579.	1.6	8
3	PK2/PKR1 Signaling Regulates Bladder Function and Sensation in Rats with Cyclophosphamide-Induced Cystitis. Mediators of Inflammation, 2015, 2015, 1-9.	1.4	10
4	Increased Expression of Neuregulin 1 and erbB2 Tyrosine Kinase in the Bladder of Rats With Cyclophosphamide-Induced Interstitial Cystitis. International Neurourology Journal, 2015, 19, 158-163.	0.5	3
5	Editorial Comment from Dr Tomoe to Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response. International Journal of Urology, 2015, 22, 841-842.	0.5	2
6	Effect of local estrogen therapy (LET) on urinary and sexual symptoms in premenopausal women with interstitial cystitis/bladder pain syndrome (IC/BPS). Gynecological Endocrinology, 2015, 31, 828-832.	0.7	20
7	Update in Diagnosis and Treatment of Chronic Pelvic Pain Syndromes. Current Bladder Dysfunction Reports, 2015, 10, 198-206.	0.2	1
8	Chronic Pelvic Pain in Women: An Epidemiological Perspective. Women's Health, 2015, 11, 851-864.	0.7	41
9	The Challenges of Interstitial Cystitis: Current Status and Future Prospects. Drugs, 2015, 75, 2057-2063.	4.9	22
10	Is a Sexual Dysfunction Domain Necessary to UPOINT System for Women with Interstitial Cystitis/Bladder Pain Syndrome-A Comment. , 2016, 5, .		0
11	Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis—Different Mechanisms of Action of Botox on Bladder Dysfunction?. Toxins, 2016, 8, 75.	1.5	17
12	Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature. Toxins, 2016, 8, 88.	1.5	26
13	Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action. Toxins, 2016, 8, 120.	1.5	33
14	Transgenic Mice Expressing MCP-1 by the Urothelium Demonstrate Bladder Hypersensitivity, Pelvic Pain and Voiding Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study. PLoS ONE, 2016, 11, e0163829.	1.1	15
15	Evidence for the Role of Mast Cells in Cystitis-Associated Lower Urinary Tract Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study. PLoS ONE, 2016, 11, e0168772.	1.1	35
16	Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015. International Journal of Urology, 2016, 23, 542-549.	0.5	100
17	Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice. American Journal of Physiology - Renal Physiology, 2016, 311, F85-F93.	1.3	28
18	Spinal astrocytic activation contributes to mechanical allodynia in a rat model of cyclophosphamide-induced cystitis. Molecular Pain, 2016, 12, 174480691667447.	1.0	26

#	ARTICLE	IF	CITATIONS
19	Blocking PAR2 alleviates bladder pain and hyperactivity via TRPA1 signal. <i>Translational Neuroscience</i> , 2016, 7, 133-138.	0.7	6
21	Urinary Metabolomics Identifies a Molecular Correlate of Interstitial Cystitis/Bladder Pain Syndrome in a Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network Cohort. <i>EBioMedicine</i> , 2016, 7, 167-174.	2.7	38
22	Efficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 2016, 48, 1215-1227.	0.6	24
24	Botulinum Toxin A: Evolving Treatment Strategies for the Chronic Pelvic Pain Patient. <i>Current Bladder Dysfunction Reports</i> , 2016, 11, 277-283.	0.2	0
25	Anorectal and Pelvic Pain. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1471-1486.	1.4	56
26	F16357, a novel protease-activated receptor 1 antagonist, improves urodynamic parameters in a rat model of interstitial cystitis. <i>British Journal of Pharmacology</i> , 2016, 173, 2224-2236.	2.7	12
27	Specific inhibition of ICAM-1 effectively reduces bladder inflammation in a rat model of severe non-bacterial cystitis. <i>Scientific Reports</i> , 2016, 6, 35672.	1.6	8
28	Blocking mammalian target of rapamycin alleviates bladder hyperactivity and pain in rats with cystitis. <i>Molecular Pain</i> , 2016, 12, 174480691666886.	1.0	7
29	Use of Botulinum Toxin in Urologic Diseases. <i>Urology</i> , 2016, 91, 21-32.	0.5	16
30	Biomarkers for Interstitial Cystitis/Painful Bladder Syndrome. <i>Women's Health</i> , 2016, 12, 87-90.	0.7	12
31	Therapeutic Potential of Human Chorionic Gonadotropin Against Painful Bladder Syndrome/Interstitial Cystitis. <i>Reproductive Sciences</i> , 2016, 23, 1451-1458.	1.1	1
32	A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Urology</i> , 2016, 196, 747-754.	0.2	38
33	Investigational drugs for bladder pain syndrome (BPS) / interstitial cystitis (IC). <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 521-529.	1.9	22
34	Stem Cell Therapy for Interstitial Cystitis/Bladder Pain Syndrome. <i>Current Urology Reports</i> , 2016, 17, 1.	1.0	49
35	A Feasibility Study to Determine Whether Clinical Contrast Enhanced Magnetic Resonance Imaging can Detect Increased Bladder Permeability in Patients with Interstitial Cystitis. <i>Journal of Urology</i> , 2016, 195, 631-638.	0.2	24
36	Childhood trauma perpetrated by close others, psychiatric dysfunction, and urological symptoms in patients with interstitial cystitis/bladder pain syndrome. <i>Journal of Psychosomatic Research</i> , 2017, 93, 90-95.	1.2	27
37	Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study. <i>BMC Urology</i> , 2017, 17, 2.	0.6	22
38	Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: A review. <i>Neurourology and Urodynamics</i> , 2017, 36, 1677-1684.	0.8	63

#	ARTICLE	IF	CITATIONS
39	Which bladder instillations are more effective? DMSO vs. bupivacaine/heparin/triamcinolone: a retrospective study. <i>International Urogynecology Journal</i> , 2017, 28, 1335-1340.	0.7	13
40	A Prospective, Multicenter, Double-Blind, Randomized Trial of Bladder Instillation of Liposome Formulation OnabotulinumtoxinA for Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Urology</i> , 2017, 198, 376-382.	0.2	56
41	Bladder Capacity is a Biomarker for a Bladder Centric versus Systemic Manifestation in Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Urology</i> , 2017, 198, 369-375.	0.2	39
42	Histopathological characteristics of interstitial cystitis/bladder pain syndrome without Hunner lesion. <i>Histopathology</i> , 2017, 71, 415-424.	1.6	61
43	Clinical Efficacy of 1-Year Intensive Systematic Dietary Manipulation as Complementary and Alternative Medicine Therapies on Female Patients With Interstitial Cystitis/Bladder Pain Syndrome. <i>Urology</i> , 2017, 106, 50-54.	0.5	18
44	Anti-vascular endothelial growth factor treatment decreases bladder pain in cyclophosphamide cystitis: a Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network animal model study. <i>BJU International</i> , 2017, 120, 576-583.	1.3	20
45	Expression profile of urothelial transcription factors in bladder biopsies with interstitial cystitis. <i>International Journal of Urology</i> , 2017, 24, 632-638.	0.5	8
46	Urologic and Gynecologic Sources of Pelvic Pain. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2017, 28, 571-588.	0.7	1
47	Urogenital Pain. , 2017, , .		1
48	Evaluation of the efficacy of postmortem human bladder tissue as a normal comparator for case-controlled gene expression studies in urology. <i>Neurourology and Urodynamics</i> , 2017, 36, 1076-1080.	0.8	2
49	Functional urological disorders: a sensitized defence response in the bladder-gut-brain axis. <i>Nature Reviews Urology</i> , 2017, 14, 153-163.	1.9	74
50	Long-term outcomes of intravesical dimethyl sulfoxide/heparin/hydrocortisone therapy for interstitial cystitis/bladder pain syndrome. <i>International Urogynecology Journal</i> , 2017, 28, 1085-1089.	0.7	27
51	Improved efficacy and in vivo cellular properties of human embryonic stem cell derivative in a preclinical model of bladder pain syndrome. <i>Scientific Reports</i> , 2017, 7, 8872.	1.6	35
52	Sacral Neuromodulation for Refractory Bladder Pain Syndrome/Interstitial Cystitis: a Global Systematic Review and Meta-analysis. <i>Scientific Reports</i> , 2017, 7, 11031.	1.6	39
53	Can intravesical steroid injections cause bladder-wall calcification? A case report of a rare therapeutic complication for interstitial cystitis. <i>Journal of Clinical Urology</i> , 2017, 10, 585-586.	0.1	0
54	Characterization of Bladder and Pelvic Floor Dysfunction in Women With Chronic Pelvic Pain. <i>Journal of Women's Health Physical Therapy</i> , 2017, 41, 132-136.	0.5	4
55	Alexithymia and anesthetic bladder capacity in interstitial cystitis/bladder pain syndrome. <i>Journal of Psychosomatic Research</i> , 2017, 100, 15-21.	1.2	14
56	A standard for terminology in chronic pelvic pain syndromes: A report from the chronic pelvic pain working group of the international continence society. <i>Neurourology and Urodynamics</i> , 2017, 36, 984-1008.	0.8	142

#	ARTICLE	IF	CITATIONS
57	Important role of physicians in addressing psychological aspects of interstitial cystitis/bladder pain syndrome (IC/BPS): a qualitative analysis. <i>International Urogynecology Journal</i> , 2017, 28, 249-256.	0.7	26
58	The Burden of Bladder Pain in Five European Countries: A Cross-sectional Study. <i>Urology</i> , 2017, 99, 84-91.	0.5	12
59	Bladder telemetry: A new approach to evaluate micturition behavior under physiological and inflammatory conditions. <i>Neurourology and Urodynamics</i> , 2017, 36, 308-315.	0.8	10
60	What is the Best Treatment Option for Coexisting Pelvic Floor Dysfunctions?. <i>European Urology Focus</i> , 2017, 3, 532-534.	1.6	1
61	Bladder pain syndrome from urogynecological point of view: a narrative. <i>International Journal of Reproduction, Contraception, Obstetrics and Gynecology</i> , 2017, 6, 1694.	0.0	0
62	Treatment effectiveness in interstitial cystitis/bladder pain syndrome: Do patient perceptions align with efficacy-based guidelines?. <i>Canadian Urological Association Journal</i> , 2017, 12, E1-5.	0.3	22
63	A prospective randomized controlled multicentre trial comparing intravesical DMSO and chondroitin sulphate 2% for painful bladder syndrome/interstitial cystitis. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 134-141.	0.7	22
64	Evaluation of the incidence and risk factors associated with persistent frequency in interstitial cystitis/bladder pain syndrome and the efficacy of antimuscarinic treatment. <i>Investigative and Clinical Urology</i> , 2017, 58, 353.	1.0	17
65	Use of botulinum toxin for voiding dysfunction. <i>Translational Andrology and Urology</i> , 2017, 6, 234-251.	0.6	11
66	Bladder pain syndrome/interstitial cystitis is associated with asthma: A case-control study. <i>Neurourology and Urodynamics</i> , 2018, 37, 1773-1778.	0.8	5
67	Videourodynamic characteristics of interstitial cystitis/bladder pain syndrome—The role of bladder outlet dysfunction in the pathophysiology. <i>Neurourology and Urodynamics</i> , 2018, 37, 1971-1977.	0.8	12
68	Clinical Criteria of Central Sensitization in Chronic Pelvic and Perineal Pain (Convergences PP) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 2018, 19, 2009-2015.	0.9	51
69	Re: Long-Term Outcomes of Intravesical Dimethyl Sulfoxide/Heparin/Hydrocortisone Therapy for Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Urology</i> , 2018, 199, 897-898.	0.2	0
70	Epstein-Barr Virus as a Potential Etiology of Persistent Bladder Inflammation in Human Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Urology</i> , 2018, 200, 590-596.	0.2	35
71	Chronic pelvic pain in benign and functional urological conditions: A review and comparison of the UK and European guidelines. <i>Journal of Clinical Urology</i> , 2018, 11, 115-121.	0.1	1
73	FDA BRUDAC 2018 Criteria for Interstitial Cystitis/Bladder Pain Syndrome Clinical Trials: Future Direction for Research. <i>Journal of Urology</i> , 2018, 200, 39-42.	0.2	26
74	A genome-scale DNA methylation study in women with interstitial cystitis/bladder pain syndrome. <i>Neurourology and Urodynamics</i> , 2018, 37, 1485-1493.	0.8	13
75	Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). <i>LUTS: Lower Urinary Tract Symptoms</i> , 2018, 10, 3-11.	0.6	32

#	ARTICLE	IF	CITATIONS
76	Increased Systemic Antibiotic Use and Clostridium difficile Infection Among Outpatients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 974-976.	2.4	6
77	A Case-Crossover Study of Urological Chronic Pelvic Pain Syndrome Flare Triggers in the MAPP Research Network. <i>Journal of Urology</i> , 2018, 199, 1245-1251.	0.2	21
78	Elevated Urine Levels of Macrophage Migration Inhibitory Factor in Inflammatory Bladder Conditions: A Potential Biomarker for a Subgroup of Interstitial Cystitis/Bladder Pain Syndrome Patients. <i>Urology</i> , 2018, 116, 55-62.	0.5	26
79	Morbidity rate and medical utilization in interstitial cystitis/painful bladder syndrome. <i>International Urogynecology Journal</i> , 2018, 29, 1045-1050.	0.7	13
81	Alpha-oxoglutarate inhibits the proliferation of immortalized normal bladder epithelial cells via an epigenetic switch involving ARID1A. <i>Scientific Reports</i> , 2018, 8, 4505.	1.6	13
82	Preclinical Animal Studies of Intravesical Recombinant Human Proteoglycan 4 as a Novel Potential Therapy for Diseases Resulting From Increased Bladder Permeability. <i>Urology</i> , 2018, 116, 230.e1-230.e7.	0.5	10
83	Sensory mapping of pelvic dermatomes in women with interstitial cystitis/bladder pain syndrome. <i>Neurourology and Urodynamics</i> , 2018, 37, 458-465.	0.8	4
84	The Interstitial Cystitis/Bladder Pain Syndrome Clinical Picture: A Perspective from Patient Life Experience. <i>Urology Practice</i> , 2018, 5, 286-292.	0.2	6
85	Psychosocial co-morbidities in Interstitial Cystitis/Bladder Pain syndrome (IC/BPS): A systematic review. <i>Neurourology and Urodynamics</i> , 2018, 37, 926-941.	0.8	58
87	Stimulators and activators of soluble guanylate cyclase for urogenital disorders. <i>Nature Reviews Urology</i> , 2018, 15, 42-54.	1.9	39
88	Bladder Pain Syndrome – An Evolution. , 2018, , .		5
89	Umbilical cord-derived mesenchymal stem cells alleviated inflammation and inhibited apoptosis in interstitial cystitis via AKT/mTOR signaling pathway. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 546-552.	1.0	29
90	What Is New in Bladder Pain?. <i>Obstetrics and Gynecology</i> , 2018, 132, 1296-1299.	1.2	0
91	Recent advances in imaging and understanding interstitial cystitis. <i>F1000Research</i> , 2018, 7, 1771.	0.8	23
92	Long-Term Relief of Painful Bladder Syndrome by High-Intensity, Low-Frequency Repetitive Transcranial Magnetic Stimulation of the Right and Left Dorsolateral Prefrontal Cortices. <i>Frontiers in Neuroscience</i> , 2018, 12, 925.	1.4	15
93	An Overview of the Pathology and Emerging Treatment Approaches for Interstitial Cystitis/Bladder Pain Syndrome. <i>Cureus</i> , 2018, 10, e3321.	0.2	3
94	Endogenous H <sub>2</sub> S sensitizes PAR4-induced bladder pain. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, F1077-F1086.	1.3	7
95	Comparison of urologic and non-urologic presentation in interstitial cystitis/bladder pain syndrome patients with and without Hunner lesions. <i>Neurourology and Urodynamics</i> , 2018, 37, 2911-2918.	0.8	13

#	ARTICLE	IF	CITATIONS
96	Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium. <i>Ophthalmology</i> , 2018, 125, 1793-1802.	2.5	128
97	IL-33 mast cell axis is central in LL-37 induced bladder inflammation and pain in a murine interstitial cystitis model. <i>Cytokine</i> , 2018, 110, 420-427.	1.4	14
98	Repetitive transcranial magnetic stimulation for chronic neuropathic pain in patients with bladder pain syndrome/interstitial cystitis. <i>Neurourology and Urodynamics</i> , 2018, 37, 2678-2687.	0.8	34
99	Guideline of guidelines: bladder pain syndrome. <i>BJU International</i> , 2018, 122, 729-743.	1.3	79
100	An evaluation of the pharmacotherapy for interstitial cystitis. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1097-1108.	0.9	35
101	Sacral Nerve Root Stimulation for Bladder Pain Syndrome/Interstitial Cystitis. , 2018, , 1455-1470.		0
103	UDS in Pain Bladder Syndrome (PBS) and Overactive Pelvic Floor Dysfunction. , 2018, , 169-182.		1
104	Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction. <i>Toxins</i> , 2018, 10, 260.	1.5	14
105	Interstitial Cystitis and Sexual Dysfunction: Diagnostic Accuracy Is Essential. <i>Current Sexual Health Reports</i> , 2018, 10, 104-108.	0.4	2
106	Menthol, a unique urinary volatile compound, is associated with chronic inflammation in interstitial cystitis. <i>Scientific Reports</i> , 2018, 8, 10859.	1.6	20
107	Sub-noxious Intravesical Lipopolysaccharide Triggers Bladder Inflammation and Symptom Onset in A Transgenic Autoimmune Cystitis Model: A MAPP Network Animal Study. <i>Scientific Reports</i> , 2018, 8, 6573.	1.6	16
108	TRPV1 and the MCP-1/CCR2 Axis Modulate Post-UTI Chronic Pain. <i>Scientific Reports</i> , 2018, 8, 7188.	1.6	12
109	Bridging pharmacotherapy and minimally invasive surgery in interstitial cystitis/bladder pain syndrome treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1369-1373.	0.9	13
110	Deletion or pharmacological blockade of TLR4 confers protection against cyclophosphamide-induced mouse cystitis. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F460-F468.	1.3	16
111	Current best practice management of interstitial cystitis/bladder pain syndrome. <i>Therapeutic Advances in Urology</i> , 2018, 10, 197-211.	0.9	36
112	Current Therapeutic Strategies in Clinical Urology. <i>Molecular Pharmaceutics</i> , 2018, 15, 3010-3019.	2.3	6
113	What Is New in Neuromodulation?. <i>Current Urology Reports</i> , 2019, 20, 55.	1.0	11
114	Biomarkers in the diagnosis and symptom assessment of patients with bladder pain syndrome: a systematic review. <i>International Urogynecology Journal</i> , 2019, 30, 1785-1794.	0.7	14

#	ARTICLE	IF	CITATIONS
116	Urinary diversion in the treatment of refractory bladder pain syndrome. <i>Scandinavian Journal of Urology</i> , 2019, 53, 424-430.	0.6	3
117	Strength of Association between Pentosan Polysulfate and a Novel Maculopathy. <i>Ophthalmology</i> , 2019, 126, 1464-1466.	2.5	52
118	Bladder Hydrodistention Does Not Result in a Significant Change in Bladder Capacity for Interstitial Cystitis/Bladder Pain Syndrome Patients. <i>Urology</i> , 2019, 132, 81-86.	0.5	5
119	Long-term outcome and symptom improvement in patients with interstitial cystitis/bladder pain syndrome with or without regular follow-up and treatment. <i>Neurourology and Urodynamics</i> , 2019, 38, 1985-1993.	0.8	16
120	The misdiagnosis of interstitial cystitis/bladder pain syndrome in a VA population. <i>Neurourology and Urodynamics</i> , 2019, 38, 1966-1972.	0.8	10
121	A new look at the etiology of interstitial cystitis/bladder pain syndrome: extraordinary cultivations. <i>International Urology and Nephrology</i> , 2019, 51, 1961-1967.	0.6	7
122	Does repeated hydrodistension with transurethral fulguration for interstitial cystitis with Hunner's lesion cause bladder contraction?. <i>Arab Journal of Urology Arab Association of Urology</i> , 2019, 17, 77-81.	0.7	9
123	Histological evidence supports low anesthetic bladder capacity as a marker of a bladder-centric disease subtype in interstitial cystitis/bladder pain syndrome. <i>International Urogynecology Journal</i> , 2019, 30, 1863-1870.	0.7	23
124	Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome. <i>Toxins</i> , 2019, 11, 586.	1.5	3
125	Pharmacotherapy for Interstitial Cystitis/Bladder Pain Syndrome. <i>Current Bladder Dysfunction Reports</i> , 2019, 14, 365-376.	0.2	4
126	Using Botulinum Toxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome—Possible Pathomechanisms and Practical Issues. <i>Toxins</i> , 2019, 11, 641.	1.5	8
127	Surface-Enhanced Raman Spectroscopy (SERS) Based on ZnO Nanorods for Biological Applications. , 0, , .		5
128	Classification, Characterization, and Sub-Grouping of Interstitial Cystitis. <i>Current Bladder Dysfunction Reports</i> , 2019, 14, 294-300.	0.2	1
129	Improving clinical outcomes with lower motor voltage (3V) during stage 1 sacral neuromodulation for interstitial cystitis or bladder pain syndrome. <i>Neurourology and Urodynamics</i> , 2019, 38, 2233-2241.	0.8	10
130	How can we improve the diagnosis and management of bladder pain syndrome? Part 1: ICIERS 2018. <i>Neurourology and Urodynamics</i> , 2019, 38, S66-S70.	0.8	4
131	Phenotypic Spectrum of Pentosan Polysulfate Sodium-Associated Maculopathy. <i>JAMA Ophthalmology</i> , 2019, 137, 1275.	1.4	79
132	Management of Symptom Flares and Patient-reported Flare Triggers in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)—Findings From One Site of the MAPP Research Network. <i>Urology</i> , 2019, 126, 24-33.	0.5	17
133	Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. <i>European Urology Focus</i> , 2019, 5, 2-4.	1.6	16



#	ARTICLE	IF	CITATIONS
134	Role of NLRP3 inflammasome in the development of bladder pain syndrome interstitial cystitis. Therapeutic Advances in Urology, 2019, 11, 175628721881803.	0.9	18
135	Temperature-responsive silk-elastinlike protein polymer enhancement of intravesical drug delivery of a therapeutic glycosaminoglycan for treatment of interstitial cystitis/painful bladder syndrome. Biomaterials, 2019, 217, 119293.	5.7	30
136	Umbilical moxibustion combined with acupuncture for interstitial cystitis. World Journal of Acupuncture-moxibustion, 2019, 29, 241-243.	0.1	0
137	A longitudinal analysis of urological chronic pelvic pain syndrome flares in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (<scp>MAPP</scp>) Research Network. BJU International, 2019, 124, 522-531.	1.3	10
138	Low bladder capacity is an important predictor for comorbidity of interstitial cystitis with Hunner's lesion in patients with refractory chronic prostatitis/chronic pelvic pain syndrome. International Journal of Urology, 2019, 26, 53-56.	0.5	3
139	Phenotyping of interstitial cystitis/bladder pain syndrome. International Journal of Urology, 2019, 26, 17-19.	0.5	55
140	Common Causes, Diagnostic Evaluation, and Treatment in Women. , 2019, , 845-849.		0
141	A survey for ketamine abuse and its relation to the lower urinary tract symptoms in Taiwan. Scientific Reports, 2019, 9, 7240.	1.6	22
142	Transplant immunosuppressive drugs in urology. Translational Andrology and Urology, 2019, 8, 109-117.	0.6	8
143	Potential of hyperbaric oxygen in urological diseases. International Journal of Urology, 2019, 26, 860-867.	0.5	16
144	Variations in bladder pain syndrome/interstitial cystitis (IC) definitions, pathogenesis, diagnostics and treatment: a systematic review and evaluation of national and international guidelines. International Urogynecology Journal, 2019, 30, 1795-1805.	0.7	33
145	Is there an effective therapy of interstitial cystitis/bladder pain syndrome?. Expert Opinion on Pharmacotherapy, 2019, 20, 1417-1419.	0.9	4
146	Cystitis-induced bladder pain is Toll-like receptor 4 dependent in a transgenic autoimmune cystitis murine model: a MAPP Research Network animal study. American Journal of Physiology - Renal Physiology, 2019, 317, F90-F98.	1.3	17
147	Female lower urinary tract microbiota do not associate with IC/PBS symptoms: a case-controlled study. International Urogynecology Journal, 2019, 30, 1835-1842.	0.7	33
148	Is trigonitis a neglected, imprecise, misunderstood, or forgotten diagnosis?. LUTS: Lower Urinary Tract Symptoms, 2019, 11, 182-188.	0.6	11
149	Ulcerative interstitial cystitis in an adolescent successfully treated with complete transurethral ulcer resection: A case report. IJU Case Reports, 2019, 2, 51-53.	0.1	0
150	Anxiety severity does not influence treatment outcomes in patients with interstitial cystitis/bladder pain syndrome. Neurourology and Urodynamics, 2019, 38, 1602-1610.	0.8	3
151	Neuregulin-1/ErbB signaling promotes microglia activation contributing to mechanical allodynia of cyclophosphamide-induced cystitis. Neurourology and Urodynamics, 2019, 38, 1250-1260.	0.8	22

#	ARTICLE	IF	CITATIONS
152	Diagnosis in a Preclinical Model of Bladder Pain Syndrome Using a Au/ZnO Nanorod-based SERS Substrate. <i>Nanomaterials</i> , 2019, 9, 224.	1.9	7
154	Chronic Lower Urinary Tract Signs in Cats. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2019, 49, 187-209.	0.5	22
155	Persistent autonomic dysfunction and bladder sensitivity in primary dysmenorrhea. <i>Scientific Reports</i> , 2019, 9, 2194.	1.6	17
156	Use of Botulinum Toxin in the Genitourinary System. <i>Handbook of Experimental Pharmacology</i> , 2019, 263, 171-184.	0.9	4
157	Dysregulation of bladder corticotropin-releasing hormone receptor in the pathogenesis of human interstitial cystitis/bladder pain syndrome. <i>Scientific Reports</i> , 2019, 9, 19169.	1.6	15
158	Bladder Pain Syndrome in Women. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2435.	3.8	3
159	How can we improve the diagnosis and management of bladder pain syndrome? Part 2: ICI&E S 2018. <i>Neurourology and Urodynamics</i> , 2019, 38, S71-S81.	0.8	8
160	Is there an appropriate strategy for treating co-morbid irritable bowel syndrome and bladder pain syndrome?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 411-414.	0.9	5
161	Molecular pathogenesis of interstitial cystitis/bladder pain syndrome based on gene expression. <i>Journal of Cellular Physiology</i> , 2019, 234, 12301-12308.	2.0	18
162	Hyperbaric oxygen significantly improves frequent urination, hyperalgesia, and tissue damage in a mouse long&Elasting cystitis model induced by an intravesical instillation of hydrogen peroxide. <i>Neurourology and Urodynamics</i> , 2019, 38, 97-106.	0.8	7
163	Sensory pudendal nerve stimulation increases bladder capacity through sympathetic mechanisms in cyclophosphamide&Einduced cystitis rats. <i>Neurourology and Urodynamics</i> , 2019, 38, 135-143.	0.8	10
164	The Role of Urinary Microbiota in Lower Urinary Tract Dysfunction: A Systematic Review. <i>European Urology Focus</i> , 2020, 6, 361-369.	1.6	30
165	Female Veterans With Diagnoses of Both Chronic Pelvic Pain and Overactive Bladder; How Do They Compare to Women Diagnosed With Interstitial Cystitis?. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2020, 26, 591-593.	0.6	2
166	Choroidal Neovascularization Associated with Pentosan Polysulfate Toxicity. <i>Ophthalmology Retina</i> , 2020, 4, 111-113.	1.2	20
167	Effect of investigative laparoscopy on bladder pain syndrome: a prospective cohort trial. <i>International Urogynecology Journal</i> , 2020, 31, 1583-1591.	0.7	3
168	Pentosan Polysulfate Sodium Exposure and Drug-Induced Maculopathy in Commercially Insured Patients in the United States. <i>Ophthalmology</i> , 2020, 127, 535-543.	2.5	30
169	Increased Transient Receptor Potential Melastatin 8 Expression in the Development of Bladder Pain in Patients With Interstitial Cystitis/Bladder Pain Syndrome. <i>Urology</i> , 2020, 146, 301.e1-301.e6.	0.5	8
171	Bladder Pain Syndrome/Interstitial Cystitis due to Pudendal Nerve Compression: Described in 1915&E”A Reminder for Treating Pelvic Pain a Century Later. <i>Journal of Brachial Plexus and Peripheral Nerve Injury</i> , 2020, 15, e5-e8.	1.0	3

#	ARTICLE	IF	CITATIONS
172	Visual Function in Pentosan Polysulfate Sodium Maculopathy. , 2020, 61, 33.		9
173	Comparison of intravesical instillation of hyaluronic acid with intradetrusor botulinum toxin A injection or cystoscopic hydrodistention for ketamine-associated cystitis. Journal of International Medical Research, 2020, 48, 030006052097310.	0.4	4
174	Pharmacotherapeutic advances for recurrent urinary tract infections in women. Expert Opinion on Pharmacotherapy, 2020, 21, 2011-2026.	0.9	6
175	A protocol of systematic review and meta-analysis of neuromuscular electrical stimulation for interstitial cystitis. Medicine (United States), 2020, 99, e21088.	0.4	0
176	Evaluation of the efficacy of Chinese herbal medicine and acupuncture for the prevention of mental disorders in interstitial cystitis patients. Medicine (United States), 2020, 99, e21422.	0.4	1
177	Percutaneous tibial nerve stimulation for the treatment of interstitial cystitis/bladder pain syndrome: a pilot study. International Urogynecology Journal, 2021, 32, 2757-2764.	0.7	13
178	Understanding and Redefining the Role of Urodynamics in Pelvic Floor Disorders. Current Bladder Dysfunction Reports, 2020, 15, 127-134.	0.2	0
179	An adaptive randomized clinical trial in interstitial cystitis/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner's lesions. World Journal of Urology, 2021, 39, 2065-2071.	1.2	10
180	Effects of non-ablative vaginal erbium:YAG laser treatment for interstitial cystitis/bladder pain syndrome: a case series (UNICORN-2 study). Climacteric, 2020, 23, S14-S17.	1.1	8
181	Qualitative analysis of treatment needs in interstitial cystitis/bladder pain syndrome: Implications for intervention. Canadian Journal of Pain, 2020, 4, 181-198.	0.6	13
183	Presenting an atlas of Hunner lesions in interstitial cystitis which can be identified with office cystoscopy. Neurourology and Urodynamics, 2020, 39, 2394-2400.	0.8	17
184	Characterization and Validation of a Chronic Model of Cyclophosphamide-Induced Interstitial Cystitis/Bladder Pain Syndrome in Rats. Frontiers in Pharmacology, 2020, 11, 1305.	1.6	33
186	Pain reduction realized with extracorporeal shock wave therapy for the treatment of symptoms associated with interstitial cystitis/bladder pain syndrome—A prospective, multicenter, randomized, double-blind, placebo-controlled study. Neurourology and Urodynamics, 2020, 39, 1505-1514.	0.8	27
187	Pudendal neuromodulation for pelvic pain. Current Bladder Dysfunction Reports, 2020, 15, 113-120.	0.2	1
188	Guidance for gynecologists utilizing telemedicine during COVID-19 pandemic based on expert consensus and rapid literature reviews. International Journal of Gynecology and Obstetrics, 2020, 150, 288-298.	1.0	12
189	Application of Adult and Pluripotent Stem Cells in Interstitial Cystitis/Bladder Pain Syndrome Therapy: Methods and Perspectives. Journal of Clinical Medicine, 2020, 9, 766.	1.0	9
190	Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders—From Bench to Bedside. Toxins, 2020, 12, 166.	1.5	10
191	Cognition, Emotion, and the Bladder: Psychosocial Factors in Bladder Pain Syndrome and Interstitial Cystitis (BPS/IC). Current Bladder Dysfunction Reports, 2020, 15, 9-14.	0.2	4

#	ARTICLE	IF	CITATIONS
192	Systemic Therapy for Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC): Systematic Review of Published Trials in the Last 5 Years. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 192-202.	0.2	1
193	An update on treatment options for interstitial cystitis. <i>Przegląd Menopauzalny</i> , 2020, 19, 35-43.	0.6	13
194	Bioinformatics Approach for Identifying Novel Biomarkers and Their Signaling Pathways Involved in Interstitial Cystitis/Bladder Pain Syndrome with Hunner Lesion. <i>Journal of Clinical Medicine</i> , 2020, 9, 1935.	1.0	15
195	Understanding bladder pain syndrome/interstitial cystitis. <i>International Urogynecology Journal</i> , 2020, 31, 1495-1496.	0.7	2
196	Acylxyacyl hydrolase regulates voiding activity. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, F1006-F1016.	1.3	8
197	The effects of botulinum toxin injection on urodynamic changes in pediatric population with neurospastic bladder: First trial in Iran. <i>Journal of Pediatric Surgery</i> , 2020, 55, 2517-2520.	0.8	2
198	Self-perception of symptoms, medical help seeking, and self-help strategies of women with interstitial cystitis/painful bladder syndrome. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2020, 12, 183-189.	0.6	4
199	Update on the Pathophysiology of Interstitial Cystitis /Bladder Pain Syndrome. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 1-8.	0.2	5
200	Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort. <i>British Journal of Ophthalmology</i> , 2020, 104, 1093-1097.	2.1	47
201	Therapeutic Efficacy of onabotulinumtoxinA Delivered Using Various Approaches in Sensory Bladder Disorder. <i>Toxins</i> , 2020, 12, 75.	1.5	10
202	Pentosan-associated maculopathy: prevalence, screening guidelines, and spectrum of findings based on prospective multimodal analysis. <i>Canadian Journal of Ophthalmology</i> , 2020, 55, 116-125.	0.4	54
203	Analgesic prescribing habits and patterns of Canadian chief urology residents: A national survey. <i>Canadian Urological Association Journal</i> , 2020, 14, 199-203.	0.3	1
204	Opioid prescription use in patients with interstitial cystitis. <i>International Urogynecology Journal</i> , 2020, 31, 1215-1220.	0.7	8
205	OAB and IC/BPS: Two Conditions or a Continuum of One?. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 15-20.	0.2	0
206	Interstitial cystitis/bladder pain syndrome: The evolving landscape, animal models and future perspectives. <i>International Journal of Urology</i> , 2020, 27, 491-503.	0.5	93
207	Chlorogenic acid attenuates cyclophosphamide-induced rat interstitial cystitis. <i>Life Sciences</i> , 2020, 254, 117590.	2.0	18
208	Clinical guidelines for interstitial cystitis/bladder pain syndrome. <i>International Journal of Urology</i> , 2020, 27, 578-589.	0.5	122
209	Clinical efficacy of submucosal injection of triamcinolone acetonide in the treatment of type II/III interstitial cystitis/bladder pain syndrome. <i>BMC Urology</i> , 2020, 20, 36.	0.6	7

#	ARTICLE	IF	CITATIONS
210	Normalization of magnesium deficiency attenuated mechanical allodynia, depressive-like behaviors, and memory deficits associated with cyclophosphamide-induced cystitis by inhibiting TNF- $\alpha$ /NF- $\kappa$ B signaling in female rats. <i>Journal of Neuroinflammation</i> , 2020, 17, 99.	3.1	26
211	Ozone Therapy in Refractory Pelvic Pain Syndromes Secondary to Cancer Treatment: A New Approach Warranting Exploration. <i>Journal of Palliative Medicine</i> , 2021, 24, 97-102.	0.6	5
212	Characterization and Prevalence of Female Pelvic Pain in a General Outpatient Urology Population. <i>Urology</i> , 2021, 151, 13-18.	0.5	1
213	Long-term outcomes of ulcerative interstitial cystitis after complete transurethral resection with therapeutic hydrodistention. <i>International Urology and Nephrology</i> , 2021, 53, 219-227.	0.6	4
214	Biomaterial-assisted drug delivery for interstitial cystitis/bladder pain syndrome treatment. <i>Journal of Materials Chemistry B</i> , 2021, 9, 23-34.	2.9	16
215	Shionone alleviates NLRP3 inflammasome mediated pyroptosis in interstitial cystitis injury. <i>International Immunopharmacology</i> , 2021, 90, 107132.	1.7	21
216	Autoimmunity to urothelial antigen causes bladder inflammation, pelvic pain, and voiding dysfunction: a novel animal model for Hunner-type interstitial cystitis. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, F174-F182.	1.3	13
217	Managing Interstitial Cystitis/Bladder Pain Syndrome in Older Adults. <i>Drugs and Aging</i> , 2021, 38, 1-16.	1.3	2
218	A high molecular weight hyaluronic acid biphasic dispersion as potential therapeutics for interstitial cystitis. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2021, 109, 864-876.	1.6	8
219	Comparative effectiveness and safety of intravesical instillation treatment of interstitial cystitis/bladder pain syndrome: a systematic review and network meta-analysis of randomized controlled trials. <i>International Urogynecology Journal</i> , 2021, 32, 1061-1071.	0.7	10
220	Does cystoscopy method affect the investigation of bladder pain syndrome/interstitial cystitis?. <i>International Urogynecology Journal</i> , 2021, 32, 1229-1235.	0.7	3
221	First-line treatment posterior tibial nerve stimulation in patients with interstitial cystitis/bladder pain syndrome. <i>Central European Journal of Urology</i> , 2021, 74, 208-214.	0.2	0
222	Relationship between the frequency of electrocautery of Hunner lesions and changes in bladder capacity in patients with Hunner type interstitial cystitis. <i>Scientific Reports</i> , 2021, 11, 105.	1.6	10
224	Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm. <i>Scientific Reports</i> , 2021, 11, 914.	1.6	32
225	Efficacy of Clorpactin in refractory bladder pain syndrome/interstitial cystitis: a randomized controlled trial. <i>International Urogynecology Journal</i> , 2021, 32, 1177-1183.	0.7	4
226	Women's Experiences of Interstitial Cystitis/Painful Bladder Syndrome. <i>Western Journal of Nursing Research</i> , 2022, 44, 125-132.	0.6	8
227	Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis. <i>International Urogynecology Journal</i> , 2021, 32, 1129-1141.	0.7	14
228	Beneficial effect of <i>Bletilla striata</i> extract solution on zymosan-induced interstitial cystitis in rat. <i>Neurourology and Urodynamics</i> , 2021, 40, 763-770.	0.8	5

#	ARTICLE	IF	CITATIONS
229	SuperGAG biopolymers for treatment of excessive bladder permeability. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00709.	1.1	6
231	Comparison of deep phenotyping features of UCPPS with and without Hunner lesion: A MAPPâ€œ Research Network Study. <i>Neurourology and Urodynamics</i> , 2021, 40, 810-818.	0.8	7
232	The chicken or the egg: Longitudinal changes in pain and catastrophizing in women with interstitial cystitis/bladder pain syndrome. <i>Canadian Urological Association Journal</i> , 2021, 15, 326-331.	0.3	3
233	Non-venous Pelvic Pain and Roles for Pelvic Floor PT or Pudendal Nerve Blocks. <i>Techniques in Vascular and Interventional Radiology</i> , 2021, 24, 100735.	0.4	1
234	Examination of pelvic floor muscle elasticity in patients with interstitial cystitis/bladder pain syndrome using real-time tissue elastography. <i>International Urogynecology Journal</i> , 2022, 33, 619-626.	0.7	6
235	Pain Management in a Model of Interstitial Cystitis/Bladder Pain Syndrome by a Vaccinal Strategy. <i>Frontiers in Pain Research</i> , 2021, 2, 642706.	0.9	5
236	Relationship of Pain Catastrophizing With Urinary Biomarkers in Women With Bladder Pain Syndrome. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2021, 27, 746-752.	0.6	3
237	Myofascial Pelvic Pain: An Overlooked and Treatable Cause of Chronic Pelvic Pain. <i>Journal of Midwifery and Women's Health</i> , 2021, 66, 148-160.	0.7	25
238	Update on maculopathy secondary to pentosan polysulfate toxicity. <i>Current Opinion in Ophthalmology</i> , 2021, 32, 233-239.	1.3	1
239	Does Pollen Trigger Urological Chronic Pelvic Pain Syndrome Flares? A Case-Crossover Analysis in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network. <i>Journal of Urology</i> , 2021, 205, 1133-1138.	0.2	3
240	The efficacy of manipulation as a treatment for myofascial pelvic pain. <i>International Urology and Nephrology</i> , 2021, 53, 1339-1343.	0.6	5
241	Clinical Remission Using Personalized Low-Dose Intravenous Infusions of N-acetylcysteine with Minimal Toxicities for Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Personalized Medicine</i> , 2021, 11, 342.	1.1	1
242	Bladder Instillations With Triamcinolone Acetonide for Interstitial Cystitisâ€œBladder Pain Syndrome. <i>Obstetrics and Gynecology</i> , 2021, 137, 810-819.	1.2	3
243	Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo. <i>Scientific Reports</i> , 2021, 11, 7558.	1.6	10
244	Comorbidities in a Nationwide, Heterogenous Population of Veterans with Interstitial Cystitis/Bladder Pain Syndrome. <i>Urology</i> , 2021, 156, 37-43.	0.5	4
245	Decreased urothelial cytoskeleton and cell proliferation protein expression suggest interstitial cystitis/bladder pain syndrome patients with Hunnerâ€™s lesion and gradeâ€œ3 glomerulation might be different from other types of patients. <i>International Journal of Urology</i> , 2021, 28, 823-830.	0.5	15
246	Comparative safety review of current pharmacological treatments for interstitial cystitis/ bladder pain syndrome. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1049-1059.	1.0	4
247	Novel Applications of Non-Invasive Intravesical Botulinum Toxin a Delivery in the Treatment of Functional Bladder Disorders. <i>Toxins</i> , 2021, 13, 359.	1.5	11

#	ARTICLE	IF	CITATIONS
248	The effect of mindfulness-based stress reduction on the urinary microbiome in interstitial cystitis. <i>International Urogynecology Journal</i> , 2022, 33, 665-671.	0.7	3
249	Pentosan polysulfate maculopathy. <i>Survey of Ophthalmology</i> , 2022, 67, 83-96.	1.7	21
250	Voiding dysfunctions in patients with non-Hunner's ulcer interstitial cystitis/bladder pain syndrome do not affect long-term treatment outcome. <i>International Journal of Clinical Practice</i> , 2021, 75, e14372.	0.8	2
252	Current Status of Intravesical Therapies for Bladder Pain Syndrome (BPS): A Narrative Review of Emerging Evidence. <i>Urology</i> , 2021, 156, e48-e57.	0.5	5
253	Comparison of bladder autoaugmentation by transurethral vesicomyotomy and hydrodistention for ketamine cystitis. <i>Translational Andrology and Urology</i> , 2021, 10, 2351-2361.	0.6	3
254	Chronic psychological stress and lower urinary tract symptoms. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 414-424.	0.6	27
255	The Value of Cystoscopy in the Assessment of Interstitial Cystitis/Bladder Pain Syndrome. <i>Acta Biomedica Scientifica</i> , 2021, 6, 198-204.	0.1	0
256	Trigone as a diagnostic and therapeutic target for bladder-centric interstitial cystitis/bladder pain syndrome. <i>International Urogynecology Journal</i> , 2021, 32, 3105-3111.	0.7	8
257	A Systematic Review of Therapeutic Approaches Used in Experimental Models of Interstitial Cystitis/Bladder Pain Syndrome. <i>Biomedicines</i> , 2021, 9, 865.	1.4	16
258	Clinical Presentation of Urologic Chronic Pelvic Pain Syndrome (UCPPS) Varies With Presenting Age – Implication on Patient Evaluation. <i>Urology</i> , 2021, , .	0.5	1
259	Effect of focal and diffuse hypervascularization as cystoscopic findings on predicting intravesical therapy response in patients with bladder pain syndrome. , 2021, 47, 325-337.		2
260	Unanticipated cystoscopic findings at the time of planned hydrodistension for bladder pain syndrome. <i>International Urogynecology Journal</i> , 2021, , 1.	0.7	0
261	Comparison of Pelvic Floor Physical Therapy Attendance Based on Referring Provider Specialty. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2022, 28, 57-63.	0.6	3
262	Low energy shock wave therapy attenuates mitochondrial dysfunction and improves bladder function in HCl induced cystitis in rats. <i>Biomedical Journal</i> , 2022, 45, 482-490.	1.4	11
263	Is Tadalafil an Effective Treatment Option for Interstitial Cystitis/Painful Bladder Syndrome? A Report of a Challenging Case. <i>Cureus</i> , 2021, 13, e16717.	0.2	0
264	PENTOSAN POLYSULFATE AND VISION. <i>Retina</i> , 2021, 41, 1562-1569.	1.0	5
265	Using the UPOINT system to manage men with chronic pelvic pain syndrome. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 387-393.	0.7	8
266	Interstitial Cystitis/Bladder Pain Syndrome Treatment: A Systematic Review of Sexual Health Outcomes. <i>Sexual Medicine Reviews</i> , 2022, 10, 71-76.	1.5	5

#	ARTICLE	IF	CITATIONS
267	The study on the function and cell source of interleukin-6 in interstitial cystitis/bladder painful syndrome rat model. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1520-1528.	1.3	6
268	Pilot randomized controlled trial of a hypnosis intervention for women with bladder pain syndrome. <i>Neurourology and Urodynamics</i> , 2021, 40, 1945-1954.	0.8	6
269	circTHBS1 facilitates the progression of interstitial cystitis depending on the regulation of miR-139-5p/MFN2 axis. <i>Drug Development Research</i> , 2022, 83, 351-361.	1.4	2
270	Quel traitement pour le syndrome de la vessie douloureuse/cystite interstitielle en 2021 en France? <i>Progrès En Urologie - FMC</i> , 2021, 31, F69-F75.	0.2	0
271	A Novel Use of Cyclobenzaprine and Hyoscyamine (BLAVACARE TM) Impregnated Vaginal Suppositories for the Symptomatic Treatment of Interstitial Cystitis, Bladder Spasms, and Painful Bladder Syndrome. <i>Uro</i> , 2021, 1, 195-197.	0.3	0
272	YouTube™ as a source of information on bladder pain syndrome: A contemporary analysis. <i>Neurourology and Urodynamics</i> , 2022, 41, 237-245.	0.8	24
273	Interstitial cystitis/bladder pain syndrome patient is associated with subsequent increased risks of outpatient visits and hospitalizations: A population-based study. <i>PLoS ONE</i> , 2021, 16, e0256800.	1.1	4
274	Nanoparticle-mediated intravesical delivery of conditioned medium derived from mesenchymal stem cells for interstitial cystitis/bladder pain syndrome treatment. <i>Applied Materials Today</i> , 2021, 24, 101144.	2.3	3
275	Possible Association between Bladder Wall Morphological Changes on Computed Tomography and Bladder-Centered Interstitial Cystitis/Bladder Pain Syndrome. <i>Biomedicines</i> , 2021, 9, 1306.	1.4	11
276	The bladder microbiome and interstitial cystitis. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, Publish Ahead of Print, 469-473.	0.9	3
277	Acyloxyacyl hydrolase is a host determinant of gut microbiome-mediated pelvic pain. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2021, 321, R396-R412.	0.9	3
278	Management of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients. , 0, , .		0
279	The diagnostic and therapeutic efficacy of cystoscopy with hydrodistension and random biopsies in clinically suspected interstitial cystitis/bladder pain syndrome. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 265, 156-161.	0.5	4
280	Lower urinary tract function and disorders. , 2022, , 461-494.e6.		0
281	Current standard of care in treatment of bladder pain syndrome/interstitial cystitis. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110224.	0.9	12
282	Long-term Outcomes of Sacral Nerve Stimulation in Pelvic Floor Dysfunctions. <i>International Neurourology Journal</i> , 2021, 25, 319-326.	0.5	8
283	Gabapentin reduces painful bladder hypersensitivity in rats with lipopolysaccharide-induced chronic cystitis. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00697.	1.1	6
284	Interstitial Cystitis: The Painful Bladder Syndrome. , 2017, , 211-228.		1



#	ARTICLE	IF	CITATIONS
285	Anti-Allergic Compounds in Chronic Pelvic Pain. , 2017, , 153-163.		1
286	Management of Interstitial Cystitis/Bladder Pain Syndrome with Tricyclic Antidepressants. , 2017, , 107-117.		2
287	Dysuria. , 2018, , 451-464.		1
288	Pentosan Polysulfateâ€Associated Macular Disease in Patients With Interstitial Cystitis. Obstetrics and Gynecology, 2020, 135, 1091-1094.	1.2	8
289	PENTOSAN POLYSULFATE SODIUM-INDUCED PIGMENTARY MACULOPATHY WITH NONLEAKING CYSTOID MACULAR EDEMA SUCCESSFULLY TREATED WITH ANTIâ€VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. 0.3 Retinal Cases and Brief Reports, 2022, 16, 482-485.	0.3	12
290	Development of an interstitial cystitis risk score for bladder permeability. PLoS ONE, 2017, 12, e0185686.	1.1	18
291	Progressive Maculopathy After Discontinuation of Pentosan Polysulfate Sodium. Ophthalmic Surgery Lasers and Imaging Retina, 2019, 50, 656-659.	0.4	32
292	Novel research approaches for interstitial cystitis/bladder pain syndrome: thinking beyond the bladder. Translational Andrology and Urology, 2015, 4, 524-33.	0.6	25
293	In what type of interstitial cystitis/bladder pain syndrome is DMSO intravesical instillation therapy effective?. Translational Andrology and Urology, 2015, 4, 600-4.	0.6	28
294	Review of intravesical therapies for bladder pain syndrome/interstitial cystitis. Translational Andrology and Urology, 2015, 4, 629-37.	0.6	16
295	Similarities between interstitial cystitis/bladder pain syndrome and vulvodynia: implications for patient management. Translational Andrology and Urology, 2015, 4, 643-52.	0.6	22
296	A multidisciplinary approach to the evaluation and management of interstitial cystitis/bladder pain syndrome: an ideal model of care. Translational Andrology and Urology, 2015, 4, 611-9.	0.6	27
297	Interstitial cystitis/painful bladder syndrome: diagnostic evaluation and therapeutic response in a private urogynecology unit. Translational Andrology and Urology, 2015, 4, 620-3.	0.6	2
298	Current guidelines in the management of interstitial cystitis. Translational Andrology and Urology, 2015, 4, 677-83.	0.6	13
299	Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. Investigative and Clinical Urology, 2020, 61, S33.	1.0	33
300	Cystoscopic evaluation and clinical phenotyping in interstitial cystitis/bladder pain syndrome. Journal of the Turkish German Gynecology Association, 2019, 20, 117-122.	0.2	7
301	Is It Possible to Prevent Symptom Recurrence After Transurethral Resection for Hunner Lesion?. International Neurourology Journal, 2018, 22, 145-148.	0.5	1
302	Therapeutic Endoscopic Treatment Plus Maintenance Dimethyl Sulfoxide Therapy Prolongs Recurrence-Free Time in Patients With Hunner Type Interstitial Cystitis: A Pilot Study. International Neurourology Journal, 2019, 23, 327-333.	0.5	3

#	ARTICLE	IF	CITATIONS
303	Circulating sex steroids and bladder pain sensitivity in dysmenorrhea. <i>Molecular Pain</i> , 2021, 17, 174480692110352.	1.0	4
304	An experimental model of the epithelial to mesenchymal transition and pro-fibrogenesis in urothelial cells related to bladder pain syndrome/interstitial cystitis. <i>Translational Andrology and Urology</i> , 2021, 10, 4120-4131.	0.6	5
305	Neuroinflammatory gene expression analysis reveals potential novel mediators and treatment targets in interstitial cystitis with Hunner lesions. <i>Translational Andrology and Urology</i> , 2021, 10, 4100-4109.	0.6	4
306	Cystectomy for patients with Hunner-type interstitial cystitis at a tertiary referral center in Japan. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2022, 14, 102-108.	0.6	5
307	Low-pressure hydrodistension induces bladder glomerulations in female patients with interstitial cystitis/bladder pain syndrome. <i>Neurourology and Urodynamics</i> , 2022, 41, 296-305.	0.8	4
308	Estrogen inhibits bladder overactivity in rats with cyclophosphamide-induced cystitis via downregulating the expression of P2X3 receptors in bladder epithelium cells. <i>Neurourology and Urodynamics</i> , 2022, 41, 174-187.	0.8	1
309	How do women with interstitial cystitis/bladder pain syndrome make treatment choices?. <i>International Urogynecology Journal</i> , 2021, 33, 583.	0.7	5
310	Notch1 Signaling Contributes to Mechanical Allodynia Associated with Cyclophosphamide-Induced Cystitis by Promoting Microglia Activation and Neuroinflammation. <i>Mediators of Inflammation</i> , 2021, 2021, 1-9.	1.4	3
312	Multidisciplinary Approach to Chronic Pelvic Pain. <i>Journal of Neurology and Experimental Neuroscience</i> , 0, , .	0.2	0
313	Problems in Female Urology: Interstitial Cystitis/Bladder Pain Syndrome, Pelvic Floor Disorders, and Pelvic Organ Prolapse. , 2016, , 269-294.		0
314	Immunomodulators for Interstitial Cystitis/Bladder Pain Syndrome. , 2017, , 227-236.		0
315	The Evolution of Therapy for Chronic Pelvic Pain. , 2017, , 1-14.		1
316	Chronic Pelvic Pain of Urogynecologic Origin. , 2017, , 119-142.		0
317	Therapy for Interstitial Cystitis/Bladder Pain Syndrome and Other Forms of Pelvic Pain During Pregnancy. , 2017, , 245-270.		0
318	Bladder Surface Mucin Analogues. , 2017, , 119-137.		0
319	Diet Therapy in the Context of Chronic Pelvic Pain. , 2017, , 51-83.		0
320	Commentary on Sant Chapter: 30 Years on!. , 2018, , 69-72.		0
321	Botulinum Toxin in Treatment of Bladder Pain Syndrome/Interstitial Cystitis. , 2018, , 101-104.		0

#	ARTICLE	IF	CITATIONS
322	Partial Denervation Procedures for Bladder Pain Syndrome. , 2018, , 143-144.		0
323	Viszeraler Schmerz. , 2018, , 1-14.		0
324	Viszeraler Schmerz. , 2018, , 1-10.		0
325	The effect of Hydrodistension in combination with Pentosan Polysulfate on treatment outcomes and compliance in the treatment of bladder pain syndrome. Pakistan Journal of Medical Sciences, 2018, 35, 189-194.	0.3	4
326	Pijnlijkeblaassyndroom/interstitiële cystitis bij vrouwen. , 2019, , 712-714.		0
327	Viszeraler Schmerz. Springer Reference Medizin, 2019, , 399-408.	0.0	0
329	Interstitial Cystitis/Bladder Pain Syndrome. , 2020, , 461-470.		0
330	Bladder Pain Syndrome: A Review. European Medical Journal Urology, 0, , .	0.0	1
331	Treatment of Interstitial Cystitis/Bladder Pain Syndrome: A Contemporary Review. European Medical Journal (Chelmsford, England), 0, , .	3.0	2
332	The Level of Epidermal Growth Factor and Its Relationship with Leukocytes and Mast Cells in Experimental Interstitial Cystitis / Painful Bladder Syndrome. Urology Herald, 2020, 7, 20-28.	0.1	0
334	Commentary on "New Frontiers or the Treatment of Interstitial Cystitis/Bladder Pain Syndrome-Focused on Stem Cells, Platelet-Rich Plasma, and Low-Energy Shock Wave". International Neurourology Journal, 2020, 24, 387-388.	0.5	0
335	Clinical manifestations and results of cystoscopy in women with interstitial cystitis/bladder pain syndrome. İstanbul Kuzey Klinikleri, 2020, 7, 417-424.	0.1	1
336	Botulinum Toxin Treatment in Urological Disorders. , 2020, , 297-308.		0
337	Problems in Female Urology: Interstitial Cystitis/Bladder Pain Syndrome, Pelvic Floor Disorders, and Pelvic Organ Prolapse. , 2020, , 309-343.		0
338	Chronic pelvic pain: from correct diagnosis to adequate therapy. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2020, 12, 12-16.	0.2	7
339	Unsupervised Machine Learning Approaches Reveal Distinct Phenotypes of Perceived Bladder Pain: A Pilot Study. Frontiers in Pain Research, 2021, 2, .	0.9	2
340	Minimally invasive surgical treatment of bladder pain syndrome in women. Vestnik Khirurgii Imeni I I Grekova, 2021, 180, 48-51.	0.0	0
342	The enigma of men with interstitial cystitis/bladder pain syndrome. Translational Andrology and Urology, 2015, 4, 668-76.	0.6	9

#	ARTICLE	IF	CITATIONS
343	Bladder pain in an LL-37 interstitial cystitis and painful bladder syndrome model. American Journal of Clinical and Experimental Urology, 2017, 5, 10-17.	0.4	2
344	Evaluation of several botulinum toxins-A delivering systems into the bladder in interstitial cystitis/painful bladder syndrome (IC/PBS). American Journal of Clinical and Experimental Urology, 2019, 7, 346-351.	0.4	1
345	Assessing bladder hyper-permeability biomarkers using molecularly-targeted MRI. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10, 57-65.	1.0	4
347	Biomarkers in bladder pain syndrome: A new narrative. , 2022, , 527-538.		0
348	Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future Perspectives. Diagnostics, 2021, 11, 2238.	1.3	12
349	The Urinary Proteomic Profile Implicates Key Regulators for Urologic Chronic Pelvic Pain Syndrome (UCPPS): A MAPP Research Network Study. Molecular and Cellular Proteomics, 2022, 21, 100176.	2.5	1
350	Association of Interstitial Cystitis/Bladder Pain Syndrome with Stress-Related Diseases: A Nationwide Population-Based Study. Journal of Clinical Medicine, 2021, 10, 5669.	1.0	2
351	Î²-Defensin 2, an Antimicrobial Peptide, as a Novel Biomarker for Ulcerative Interstitial Cystitis; Can Î²-Defensin 2 Suspect the Dysbiosis of Urine Microbiota?. Diagnostics, 2021, 11, 2082.	1.3	3
352	Role of Surgery in Bladder Pain Syndrome. Current Bladder Dysfunction Reports, 2021, 16, 87-96.	0.2	1
353	A H2O2-activatable nanoprobe for diagnosing interstitial cystitis and liver ischemia-reperfusion injury via multispectral optoacoustic tomography and NIR-II fluorescent imaging. Nature Communications, 2021, 12, 6870.	5.8	63
354	Association of Elmiron (pentosanpolysulphate sodium) with pigmented maculopathy: An update for urologists and patients. Journal of Clinical Urology, 0, , 205141582110536.	0.1	0
355	Toward a validated diagnostic test with machine learning algorithm for interstitial cystitis. Urological Science, 2021, 32, 2.	0.2	7
356	Small Fiber Polyneuropathy May Be a Nexus Between Autonomic Nervous System Dysregulation and Pain in Interstitial Cystitis/Bladder Pain Syndrome. Frontiers in Pain Research, 2021, 2, 810809.	0.9	1
357	POTENTIAL NEW-ONSET CLINICALLY DETECTABLE PENTOSAN POLYSULFATE MACULOPATHY YEARS AFTER DRUG CESSATION. Retinal Cases and Brief Reports, 2022, 16, 724-726.	0.3	8
358	Efficacy of transcutaneous tibial nerve stimulation in the treatment of bladder pain syndrome. Current Urology, 2022, 16, 83-87.	0.4	2
359	Longitudinal Changes in the Pelvic Pain Only and Widespread Pain Phenotypes Over One Year in the MAPP-I Urologic Chronic Pelvic Pain Syndrome (UCPPS) Cohort. Urology, 2022, 161, 31-35.	0.5	4
360	Supervised machine learning algorithm identified KRT20 , BATF and TP63 as biologically relevant biomarkers for bladder biopsy specimens from interstitial cystitis/bladder pain syndrome patients. International Journal of Urology, 2022, , .	0.5	2
361	An indirect comparison meta-analysis of noninvasive intravesical instillation and intravesical injection of botulinum toxin-A in bladder disorders. International Urology and Nephrology, 2022, 54, 479-491.	0.6	4

#	ARTICLE	IF	CITATIONS
362	Management of Bladder Pain Syndrome (BPS): A Practical Guide. <i>Advances in Urology</i> , 2022, 2022, 1-9.	0.6	4
363	Daily low dose of tadalafil improves pain and frequency in bladder pain syndrome/interstitial cystitis patients. , 2022, 48, 82-87.		4
364	Inhibition of CXCR4 in Spinal Cord and DRG with AMD3100 Attenuates Colon-Bladder Cross-Organ Sensitization. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 67-81.	2.0	3
366	Comparative effectiveness and safety of cocktail therapy versus combined sodium hyaluronate and chondroitin sulphate (Ialuril): Intravesical instillation treatment of interstitial cystitis/bladder pain syndrome, which one to use?. <i>Journal of Clinical Urology</i> , 0, , 205141582110734.	0.1	0
367	Deep dyspareunia: a narrative review of impact on sexual function and quality of life. <i>Minerva Obstetrics and Gynecology</i> , 2022, 74, .	0.5	4
368	A global perspective on improving patient care in uncomplicated urinary tract infection: expert consensus and practical guidance. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 28, 18-29.	0.9	18
369	Recomendaciones sobre el uso de las instilaciones endovesicales de Ácido hialurónico en el síndrome de dolor vesical. <i>Actas Urológicas Españolas</i> , 2022, , .	0.3	0
370	Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment. <i>Biomedicines</i> , 2022, 10, 396.	1.4	11
371	Relief of interstitial cystitis/bladder pain syndrome by spinal cord stimulation. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2022, 28, 101517.	0.2	3
373	Harnwege. , 2022, , 887-900.		0
374	The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis. <i>Tzu Chi Medical Journal</i> , 2023, 35, 31.	0.4	5
375	Loss of NLRP3 increases bacterial cystitis via IRAKM. <i>Translational Andrology and Urology</i> , 2022, 11, 268-276.	0.6	0
376	Evaluation of YouTube videos on primary bladder pain syndrome. <i>International Urogynecology Journal</i> , 2022, 33, 1251-1258.	0.7	8
377	Botulinum Toxin for Neurogenic and Non-neurogenic Bladder Pain. <i>Current Bladder Dysfunction Reports</i> , 2022, 17, 38-47.	0.2	0
378	Acute-phase proteins in cats with obstructive feline lower urinary tract disease. <i>Veterinary Clinical Pathology</i> , 2022, 51, 77-83.	0.3	2
379	The Involvement of Endothelin Pathway in Chronic Psychological Stress-Induced Bladder Hyperalgesia Through Capsaicin-Sensitive C-Fiber Afferents. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 1209-1226.	1.6	1
380	Immune cell profiles of patients with interstitial cystitis/bladder pain syndrome. <i>Journal of Translational Medicine</i> , 2022, 20, 97.	1.8	13
381	Defining Molecular Treatment Targets for Bladder Pain Syndrome/Interstitial Cystitis: Uncovering Adhesion Molecules. <i>Frontiers in Pharmacology</i> , 2022, 13, 780855.	1.6	4

#	ARTICLE	IF	CITATIONS
382	Therapeutic Efficacy of Intravesical Platelet-Rich Plasma Injections for Interstitial Cystitis/Bladder Pain Syndrome—A Comparative Study of Different Injection Number, Additives and Concentrations. <i>Frontiers in Pharmacology</i> , 2022, 13, 853776.	1.6	5
383	Activation of translocator protein alleviates mechanical allodynia and bladder dysfunction in cyclophosphamide-induced cystitis through repression of BDNF-mediated neuroinflammation. <i>European Journal of Pain</i> , 2022, , .	1.4	4
384	Recommendations on the use of intravesical hyaluronic acid instillations in bladder pain syndrome. <i>Actas Urológicas Españolas (English Edition)</i> , 2022, 46, 131-137.	0.2	2
385	Prevalence of Overactive Bladder Symptoms Among Women With Interstitial Cystitis/Bladder Pain Syndrome. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2022, 28, e115-e119.	0.6	2
386	Reduction of Bladder Capacity Under Anesthesia Following Multiple Recurrences and Repeated Surgeries of Hunner Lesions in Patients With Interstitial Cystitis. <i>International Neurourology Journal</i> , 2022, 26, 45-51.	0.5	3
387	Identification of diagnostic serum biomarkers for Hunner-type interstitial cystitis. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2022, 14, 334-340.	0.6	1
388	Comorbidities of bladder pain syndrome in the context of the HITOP distress category: a systematic review and meta-analysis. <i>International Urogynecology Journal</i> , 2022, 33, 2335-2356.	0.7	2
390	Extracellular vesicles derived from mesenchymal stem cells alleviate neuroinflammation and mechanical allodynia in interstitial cystitis rats by inhibiting NLRP3 inflammasome activation. <i>Journal of Neuroinflammation</i> , 2022, 19, 80.	3.1	29
391	Do medication prescription patterns follow guidelines in a cohort of women with interstitial cystitis/bladder pain syndrome?. <i>Neurourology and Urodynamics</i> , 2022, , .	0.8	1
392	Comparing surgical interventions for interstitial cystitis: A systematic review. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2022, 14, 218-241.	0.6	3
393	Pentosan Polysulfate Sodium-Associated Pigmentary Retinopathy: Risk Factors and Fundus Findings. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 4809-4816.	0.9	4
394	The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 793964.	2.2	13
395	Components of the Endogenous Cannabinoid System as Potential Biomarkers for Interstitial Cystitis/Bladder Pain Syndrome. <i>Diagnostics</i> , 2022, 12, 19.	1.3	3
396	Pelvic Floor Muscle Training in the Management of Female Pelvic Floor Disorders. <i>Current Bladder Dysfunction Reports</i> , 2022, 17, 115-124.	0.2	1
397	Chemodervation in Urology. <i>Urologic Clinics of North America</i> , 2022, 49, 263-272.	0.8	0
398	New therapeutic approach with extracellular vesicles from stem cells for intestinal cystitis/bladder pain syndrome.. <i>BMB Reports</i> , 2022, , .	1.1	0
399	Age-Related Macular Degeneration Masquerade: A Review of Pentosan Polysulfate Maculopathy and Implications for Clinical Practice. <i>Asia-Pacific Journal of Ophthalmology</i> , 2022, 11, 100-110.	1.3	3
400	Imatinib Mesylate Reduces Neurotrophic Factors and pERK and pAKT Expression in Urinary Bladder of Female Mice With Cyclophosphamide-Induced Cystitis. <i>Frontiers in Systems Neuroscience</i> , 2022, 16, 884260.	1.2	2

#	ARTICLE	IF	CITATIONS
401	Clinical Phenotyping for Pain Mechanisms in Urologic Chronic Pelvic Pain Syndromes: A MAPP Research Network Study. <i>Journal of Pain</i> , 2022, 23, 1594-1603.	0.7	5
402	Reply to a letter to the editor regarding the published article: "YouTube" as a source of information on bladder pain syndrome: A contemporary analysis. <i>Neurourology and Urodynamics</i> , 2022, 41, 1194-1196.	0.8	3
403	Step-wise Treatment of Bladder Pain Syndrome: Case Report. <i>Lietuvos Chirurgija</i> , 2022, 21, 34-40.	0.0	0
404	Flavonoid Nobiletin Attenuates Cyclophosphamide-Induced Cystitis in Mice through Mechanisms That Involve Inhibition of IL-1 $\beta$ Induced Connexin 43 Upregulation and Gap Junction Communication in Urothelial Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5037.	1.8	8
405	Improved symptoms and signs of refractory interstitial cystitis in women after intravesical Nanofat plus platelet-rich plasma grafting: A pilot study. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 730-735.	0.6	6
406	Relationship Between Opioid Prescriptions and Number of Chronic Pain Conditions in Women With Interstitial Cystitis. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2022, Publish Ahead of Print, .	0.6	0
407	Present status and advances in bladder pain syndrome: central sensitisation and the urinary microbiome. <i>The Obstetrician and Gynaecologist</i> , 2022, 24, 159-166.	0.2	1
408	Imatinib Mesylate Reduces Voiding Frequency in Female Mice With Acute Cyclophosphamide-Induced Cystitis. <i>Frontiers in Systems Neuroscience</i> , 2022, 16, .	1.2	2
409	Non-Hunner's Interstitial Cystitis Is Different from Hunner's Interstitial Cystitis and May Be Curable by Uterosacral Ligament Repair. <i>Urologia Internationalis</i> , 2022, 106, 649-657.	0.6	5
410	Examining vaginal and vulvar health and sexual dysfunction in patients with interstitial cystitis (UNICORN-1 study). <i>International Urogynecology Journal</i> , 2022, 33, 2493-2499.	0.7	6
411	Bladder Oxidative Stress and HMGB1 Release Contribute to PAR4-Mediated Bladder Pain in Mice. <i>Frontiers in Systems Neuroscience</i> , 2022, 16, .	1.2	4
412	Use of Urinary Cytokine and Chemokine Levels for Identifying Bladder Conditions and Predicting Treatment Outcomes in Patients with Interstitial Cystitis/Bladder Pain Syndrome. <i>Biomedicines</i> , 2022, 10, 1149.	1.4	13
413	New therapeutic approach with extracellular vesicles from stem cells for interstitial cystitis/bladder pain syndrome. <i>BMB Reports</i> , 2022, 55, 205-212.	1.1	3
414	Pulsed Electromagnetic Field Therapy for Pain Management in Interstitial Cystitis/Bladder Pain Syndrome: A Proof-of-Concept Case Series. <i>Urology</i> , 2022, 167, 96-101.	0.5	3
415	Anti-Inflammatory Diet for Women with Interstitial Cystitis/Bladder Pain Syndrome: The AID-IC Pilot Study. <i>Methods and Protocols</i> , 2022, 5, 40.	0.9	2
416	Approach to Diagnosis and Management of Chronic Pelvic Pain in Women. <i>Obstetrics and Gynecology Clinics of North America</i> , 2022, 49, 219-239.	0.7	14
417	Therapeutic potential of nanoceria pretreatment in preventing the development of urological chronic pelvic pain syndrome: Immunomodulation via reactive oxygen species scavenging and SerpinB2 downregulation. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	7
418	A pilot study on oral cyclosporine A in association with fulguration for the treatment of interstitial cystitis with Hunner's lesions. <i>Neurourology and Urodynamics</i> , 2022, 41, 1498-1504.	0.8	1

#	ARTICLE	IF	CITATIONS
419	Prospective randomized controlled trial comparing fulguration versus fulguration and hydrodistension for Hunner-type interstitial cystitis/bladder pain syndrome. <i>World Journal of Urology</i> , 2022, 40, 2071-2076.	1.2	2
420	Prevalence, Risk Factors, Pathophysiology, Potential Biomarkers and Management of Feline Idiopathic Cystitis: An Update Review. <i>Frontiers in Veterinary Science</i> , 0, 9, .	0.9	4
421	Bladder pain syndrome/interstitial cystitis response to nerve blocks and trigger point injections. <i>BJUI Compass</i> , 0, , .	0.7	1
422	The Japanese Herbal Medicine Yokukansan Exerted Antioxidant and Analgesic Effects in an Experimental Rat Model of Hunner-Type Interstitial Cystitis. <i>Medicina (Lithuania)</i> , 2022, 58, 810.	0.8	2
423	Formulation and examination of a new urine alkalizing tablet for the symptomatic treatment of bladder pain syndrome. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 74, 103537.	1.4	0
424	Decreased autophagic activity of detrusor cells is involved in the inflammatory response of interstitial cystitis/bladder pain syndrome. <i>International Urogynecology Journal</i> , 0, , .	0.7	1
426	The Diagnosis of Chronic Pelvic Pain: How Can We Detect Urological Pain?. <i>International Neurourology Journal</i> , 2022, 26, 87-91.	0.5	0
427	Electro-Acupuncture for Bladder Pain Syndrome: A Protocol of a Randomized Controlled Trial and Study for Central Mechanism. <i>Journal of Pain Research</i> , 0, Volume 15, 1959-1970.	0.8	0
428	Clinical presentation, videourodynamic characteristics, and treatment outcome in men with interstitial cystitis-like lower urinary tract symptoms. <i>International Urology and Nephrology</i> , 0, , .	0.6	3
429	Intravesical sustained release system of lidocaine and oxybutynin results from in vitro and animal study. <i>International Urology and Nephrology</i> , 2022, 54, 2167-2174.	0.6	3
430	Nanotechnology as a tool to advance research and treatment of non-oncologic urogenital diseases. <i>Therapeutic Advances in Urology</i> , 2022, 14, 175628722211090.	0.9	0
431	Is There a Role for Bladder Biopsy in the Diagnosis of Non-Hunner Lesions Interstitial Cystitis?. <i>Urologia Internationalis</i> , 2023, 107, 257-262.	0.6	1
432	A bibliometric analysis of top-cited journal articles in interstitial cystitis and bladder pain syndrome. <i>International Urogynecology Journal</i> , 0, , .	0.7	1
433	The Role of Neuro-Immune Interaction in Chronic Pain Conditions; Functional Somatic Syndrome, Neurogenic Inflammation, and Peripheral Neuropathy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8574.	1.8	17
434	Changes in Cystoscopic Findings after Intravesical Hyaluronic Acid Instillation Therapy in Patients with Interstitial Cystitis. <i>Diagnostics</i> , 2022, 12, 2009.	1.3	4
435	Long-term Symptom Trajectories in Urologic Chronic Pelvic Pain Syndrome: A MAPP Research Network Study. <i>Urology</i> , 2022, , .	0.5	1
436	Gender differences in the experience of interstitial cystitis/bladder pain syndrome. <i>Frontiers in Pain Research</i> , 0, 3, .	0.9	5
437	Acyloxyacyl hydrolase regulates microglia-mediated pelvic pain. <i>PLoS ONE</i> , 2022, 17, e0269140.	1.1	3



#	ARTICLE	IF	CITATIONS
438	Nano-Formulation Based Intravesical Drug Delivery Systems: An Overview of Versatile Approaches to Improve Urinary Bladder Diseases. <i>Pharmaceutics</i> , 2022, 14, 1909.	2.0	14
440	Maculopathy secondary to chronic use of pentosan polysulfate sodium in treatment of interstitial cystitis. <i>Australasian journal of optometry, The</i> , 0, , 1-3.	0.6	1
441	Pigmentary Maculopathy in Interstitial Cystitis/Bladder Pain Syndrome Treated with Oral Pentosan Polysulfate: A Review. <i>European Medical Journal Urology</i> , 0, , 74-81.	0.0	0
442	Pelvic Floor Physical Therapy and Its Merit in the Treatment of Female Urogenital Pain. <i>Current Pain and Headache Reports</i> , 2022, 26, 775-782.	1.3	1
443	Recurrent triamcinolone injections for the treatment of Hunner's lesions in bladder pain syndrome. <i>Journal of Clinical Urology</i> , 0, , 205141582211225.	0.1	0
444	Bruton tyrosine kinase (BTK) may be a potential therapeutic target for interstitial cystitis/bladder pain syndrome. <i>Aging</i> , 2022, 14, 7052-7064.	1.4	1
445	Safety of Human Embryonic Stem Cell-derived Mesenchymal Stem Cells for Treating Interstitial Cystitis: A Phase I Study. <i>Stem Cells Translational Medicine</i> , 2022, 11, 1010-1020.	1.6	11
446	Cystectomy for Benign Indications. <i>Current Urology Reports</i> , 2022, 23, 195-201.	1.0	2
447	Non-Surgical Management of Chronic Pelvic Pain in Females. <i>Current Urology Reports</i> , 2022, 23, 245-254.	1.0	1
448	A shared B-cell clonotype in patients with Interstitial Cystitis/Bladder Pain Syndrome presenting with Hunner lesions. , 2022, , 100015.		1
449	Current Understanding of the Pathophysiology and Novel Treatments of Interstitial Cystitis/Bladder Pain Syndrome. <i>Biomedicines</i> , 2022, 10, 2380.	1.4	13
450	Transvaginal Photobiomodulation Improves Pain in Women with Pelvic Muscle Tenderness and Interstitial Cystitis/Bladder Pain Syndrome: A Preliminary Observational Study. <i>Urology</i> , 2022, 170, 14-20.	0.5	3
451	Multimodal Treatment with Cognitive Behavioral Therapeutic Intervention Plus Bladder Treatment Is More Effective than Monotherapy for Patients with Interstitial Cystitis/Bladder Pain Syndrome—A Randomized Clinical Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 6221.	1.0	2
452	Effectiveness of intravesical ozone in interstitial cystitis by the O'Leary's symptom index. <i>International Urogynecology Journal</i> , 2023, 34, 1437-1446.	0.7	2
453	Dehydrated Human Amnion-Chorion Membrane Extracts Can Ameliorate Interstitial Cystitis in Rats by Down-Regulating Inflammatory Cytokines and Protein Coding Genes: A Preclinical Study. <i>Life</i> , 2022, 12, 1693.	1.1	1
454	Is Erbium/Neodymium Laser Combination Therapy an Effective Treatment Option for Interstitial Cystitis/Bladder Pain Syndrome With Vulvodynia?. <i>Cureus</i> , 2022, , .	0.2	6
455	Chronic Spontaneous Urticaria in Patients With Interstitial Cystitis/Bladder Pain Syndrome: Insights From Big Data Analyses. <i>Urology</i> , 2023, 171, 83-87.	0.5	1
456	Effect of Intratrigonal Botulinum Toxin in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Long-Term, Single-Center Study in Real-Life Conditions. <i>Toxins</i> , 2022, 14, 775.	1.5	0

#	ARTICLE	IF	CITATIONS
457	Comparing concentration of urinary inflammatory cytokines in interstitial cystitis, overactive bladder, urinary tract infection, and bladder cancer. <i>Urological Science</i> , 2022, 33, 199.	0.2	4
458	Quality, Value, and Efficacy of Complementary and Alternative Medicine in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome. <i>Current Bladder Dysfunction Reports</i> , 0, , .	0.2	0
459	Preliminary Exploration of a New Therapy for Interstitial Cystitis/Bladder Pain Syndrome: Botulinum Toxin A Combined with Sapylin. <i>Toxins</i> , 2022, 14, 832.	1.5	1
460	Broaden Horizons: The Advancement of Interstitial Cystitis/Bladder Pain Syndrome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14594.	1.8	4
461	<sc>EBV</sc> infection mediated <sc>BDNF</sc> expression is associated with bladder inflammation in interstitial cystitis/bladder pain syndrome with Hunner's lesion. <i>Journal of Pathology</i> , 2023, 259, 276-290.	2.1	5
462	Treatment Outcomes of Intravesical Botulinum Toxin A Injections on Patients with Interstitial Cystitis/Bladder Pain Syndrome. <i>Toxins</i> , 2022, 14, 871.	1.5	3
463	Development of a patient-centered text message-based platform for the self-management of interstitial cystitis/bladder pain syndrome symptoms. <i>Neurourology and Urodynamics</i> , 2023, 42, 510-522.	0.8	4
464	TRPV4 activation prevents lipopolysaccharide-induced painful bladder hypersensitivity in rats by regulating immune pathways. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
465	Small-Fiber Polyneuropathy Is Prevalent in Patients With Interstitial Cystitis/Bladder Pain Syndrome. , 2022, 28, 786-792.		1
466	Diagnostic and therapeutic cystoscopy in bladder pain syndrome/interstitial cystitis: systematic review of literature and consensus on methodology. <i>International Urogynecology Journal</i> , 0, , .	0.7	2
467	Comparison of the Clinical Efficacy and Adverse Events between Intravesical Injections of Platelet-Rich Plasma and Botulinum Toxin A for the Treatment of Interstitial Cystitis Refractory to Conventional Treatment. <i>Toxins</i> , 2023, 15, 121.	1.5	1
468	An Analysis of Stated Insurance Coverage and Estimated Patient-Incurred Costs of Treatments for Lower Urinary Tract Symptoms. , 2023, 29, 287-294.		1
469	Centering Group Treatment for Women With Interstitial Cystitis/Bladder Pain Syndrome: A Prospective, Parallel-Group Cohort Study. , 2023, 29, 410-421.		0
470	Sexual dysfunction in women with interstitial cystitis/bladder pain syndrome: Do onabotulinum toxin-A injections improve sexual function?. <i>Neurourology and Urodynamics</i> , 2023, 42, 607-614.	0.8	4
471	Case report. Blokkade van de plexus hypogastricus superior en het ganglion impar bij urologische patiënten met pijn in de blaasregio. <i>Tijdschrift Voor Urologie</i> , 2023, 13, 71-74.	0.1	0
472	Immunogenic Cell Death Associated Molecular Patterns and the Dual Role of IL17RA in Interstitial Cystitis/Bladder Pain Syndrome. <i>Biomolecules</i> , 2023, 13, 421.	1.8	2
474	Endoscopic Evaluation. , 2023, , 1-16.		0
475	Platelet Lysate Therapy Attenuates Hypoxia Induced Apoptosis in Human Uroepithelial SV-HUC-1 Cells through Regulating the Oxidative Stress and Mitochondrial-Mediated Intrinsic Apoptotic Pathway. <i>Biomedicines</i> , 2023, 11, 935.	1.4	2

#	ARTICLE	IF	CITATIONS
476	Perioperative Safety of Bladder Hydrodistention in Patients on Antithrombotic Therapy. , 0, Publish Ahead of Print, .		0
477	Ileal cystoplasty and right ureterolithotomy and replantation in a patient with renal and ureteral calculi with hydronephrosis and interstitial cystitis. Asian Journal of Surgery, 2023, , .	0.2	0
478	Assessment of bladder pressure and discomfort symptoms: How do overactive bladder differ from interstitial cystitis/bladder pain syndrome patients?. BMC Urology, 2023, 23, .	0.6	1
479	The Innovative Approach in Functional Bladder Disorders: The Communication Between Bladder and Brain-Gut Axis. International Neurourology Journal, 2023, 27, 15-22.	0.5	1
480	The Evaluation and Management of Interstitial Cystitis/Bladder Pain Syndrome. European Medical Journal Urology, 0, , 75-82.	0.0	1
482	Integrated microbiome and metabolome analysis reveals novel urinary microenvironmental signatures in interstitial cystitis/bladder pain syndrome patients. Journal of Translational Medicine, 2023, 21, .	1.8	4
483	Dysuria. , 2022, , 561-575.		0
487	Pathophysiology and Clinical Evaluation of Chronic Pelvic Pain. , 2023, , 1-22.		0
502	Interstitial cystitis/bladder pain syndrome. , 2024, , 193-213.e1.		0
509	Endoscopic Evaluation. , 2023, , 179-194.		0
511	Pathophysiology and Clinical Evaluation of Chronic Pelvic Pain. , 2023, , 909-930.		0
514	Blaaspijnsyndroom/interstitiële cystitis. , 2024, , 781-784.		0
519	Image Segmentation for High-Density Surface Electromyography Mappings of Pelvic Floor Muscle Activity of Women with Interstitial Cystitis/Bladder Pain Syndrome. , 2023, , .		0
521	Pelvic Floor Awareness and Adult Re-Toilet Training in the Treatment of Lower Urinary Tract Dysfunction. , 0, , .		0